Meeting News Coverage

Adding phentermine to canagliflozin significantly increases weight loss in patients with obesity

NEW ORLEANS — The addition of phentermine to canagliflozin demonstrated significantly greater weight loss when compared with placebo in obese adults, according to results Priscilla Hollander, MD, of Baylor Medical Center, presented at the American Diabetes Association Scientific Sessions.

The study – as Hollander told Endocrine Today – looks at a new approach for weight loss in people with obesity.

“Both of these drugs have been used singly for weight loss and have been somewhat effective, but perhaps have not met the goals that we would like to see for weight loss,” she said.

Hollander and colleagues evaluated the efficacy and safety of the addition of 15 mg of phentermine to 300 mg of canagliflozin (Invokana, Janssen) in 334 adults without type 2 diabetes who had a BMI between 30 and 50 kg/m2. The four-arm, 26-week, phase 2 study also assessed the effects of canagliflozin 300 mg and phentermine 15 mg as a single agent.

Patients who received phentermine in addition to canagliflozin had weight loss of 7.5% compared with 4.1% for patients who received phentermine and 1.9% for patients who received canagliflozin. Weight loss was also statistically superior with the combination compared with placebo (P < .001).

The combination was generally well tolerated, with no new or unexpected safety signals, Hollander said.

The addition of phentermine to canagliflozin also resulted in a significant placebo-adjusted reduction in systolic blood pressure (–4.2 mm Hg; P = .015).

Hollander said that these results indicate the potential use of the drug combination as a therapy for obesity, but acknowledged more research is needed.

“It does merit further study in longer studies in patients without diabetes who are obese and also in patients with type 2 diabetes who are obese,” she said.  – by Ryan McDonald

Reference:

Hollander P, et al. 319-LB. Presented at: American Diabetes Association Scientific Sessions; June 10-14, 2016; New Orleans.

Disclosure: Hollander reports receiving research funding from Johnson and Johnson.

NEW ORLEANS — The addition of phentermine to canagliflozin demonstrated significantly greater weight loss when compared with placebo in obese adults, according to results Priscilla Hollander, MD, of Baylor Medical Center, presented at the American Diabetes Association Scientific Sessions.

The study – as Hollander told Endocrine Today – looks at a new approach for weight loss in people with obesity.

“Both of these drugs have been used singly for weight loss and have been somewhat effective, but perhaps have not met the goals that we would like to see for weight loss,” she said.

Hollander and colleagues evaluated the efficacy and safety of the addition of 15 mg of phentermine to 300 mg of canagliflozin (Invokana, Janssen) in 334 adults without type 2 diabetes who had a BMI between 30 and 50 kg/m2. The four-arm, 26-week, phase 2 study also assessed the effects of canagliflozin 300 mg and phentermine 15 mg as a single agent.

Patients who received phentermine in addition to canagliflozin had weight loss of 7.5% compared with 4.1% for patients who received phentermine and 1.9% for patients who received canagliflozin. Weight loss was also statistically superior with the combination compared with placebo (P < .001).

The combination was generally well tolerated, with no new or unexpected safety signals, Hollander said.

The addition of phentermine to canagliflozin also resulted in a significant placebo-adjusted reduction in systolic blood pressure (–4.2 mm Hg; P = .015).

Hollander said that these results indicate the potential use of the drug combination as a therapy for obesity, but acknowledged more research is needed.

“It does merit further study in longer studies in patients without diabetes who are obese and also in patients with type 2 diabetes who are obese,” she said.  – by Ryan McDonald

Reference:

Hollander P, et al. 319-LB. Presented at: American Diabetes Association Scientific Sessions; June 10-14, 2016; New Orleans.

Disclosure: Hollander reports receiving research funding from Johnson and Johnson.

    See more from Discoveries from ADA: Updates in Pharmacology